Keros Therapeutics: Pay

Keros Therapeutics paid its 3 named executives $4.8M in total in FY2025 (Dec). CEO Jasbir Seehra, Ph.D. was paid $2.5M of that.

Pay$100 in the stock at the end of FY20 → $29
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Christopher RovaldiFormer President and Chief Operating Officer
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
3 years
Jasbir Seehra, Ph.D.President and Chief Executive Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Keith RegnanteChief Financial Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)
FY2023 (Dec)
FY2021 (Dec)Not disclosed
4 years
Esther Cho, Esq.Chief Legal Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $9.5M. The CEO of Keros Therapeutics was paid $2.5M, 73% below the median.

  1. 1Scholar Rock Holding
  2. 2Protagonist Therapeutics
  3. 3Disc Medicine
  4. 4IDEAYA Biosciences
  5. 5Celldex Therapeutics
  6. 6Kura Oncology
  7. 7Relay Therapeutics
  8. 8Keros Therapeutics
  9. 9Akero Therapeutics, Inc.Not disclosed
  10. 10Arcturus Therapeutics HoldingsNot disclosed
  11. 11Crinetics Pharmaceuticals, Inc.Not disclosed
  12. 12GeronNot disclosed
  13. 13Iovance BiotherapeuticsNot disclosed
  14. 14KalVista Pharmaceuticals, Inc.Not disclosed
  15. 15Longboard Pharmaceuticals, Inc.Not disclosed
  16. 16Pliant Therapeutics, Inc.Not disclosed
  17. 17Replimune Group, Inc.Not disclosed
  18. 18Rocket Pharmaceuticals, Inc.Not disclosed
  19. 19SpringWorks Therapeutics, Inc.Not disclosed
  20. 20Syndax PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.